Abstract
PurposeTo assess the reliability and safety of a postsurgical evaluation strategy of adrenal function using CRH stimulation and basal cortisol concentrations after transsphenoidal pituitary surgery.MethodsRetrospective cohort study of all patients undergoing endoscopic transsphenoidal surgery from 2010 to 2017, in whom early postoperative basal cortisol and/or CRH-stimulated cortisol secretion were available, including confirmation of adrenal function during follow-up. Patients with Cushing’s disease were excluded. Optimal test performances were assessed using ROC analysis.ResultsA total of 156 patients were included. Sensitivity and specificity of the CRH test were 78% and 90%, respectively, and 86% and 92% for basal cortisol, respectively, using an optimal cutoff of 220 nmol/L. Eight patients had false-negative test results with the CRH test (normal test but adrenal insufficient at follow-up), and six patients with basal cortisol, the majority of which had multiple pituitary hormone deficiencies and fluid imbalances. No clinical adverse events occurred in patients with false-negative test results. The diagnostic performance of a single basal cortisol measurement was superior to the CRH test.ConclusionsThe early postoperative basal cortisol is a safe and simple measurement to guide (dis)continuation of hydrocortisone replacement. However, disturbing factors, e.g., sodium balance disorders, contraceptives, untreated hypopituitarism, and illness impact the interpretation and in those cases this measure is unreliable. We propose an algorithm in which hydrocortisone replacement at discharge is based on basal cortisol <220 nmol/L on postoperative day 2 or 3 in a stable condition.
Highlights
Transsphenoidal endoscopic surgery is the cornerstone of treatment for the majority of patients with pituitary tumors
Patients with available data on early postoperative testing and a conclusive confirmation test during follow-up were eligible for inclusion
Results of early postoperative CRH testing with subsequent insulin tolerance test (ITT) during follow-up were available in 61 patients (Fig. 2a, c)
Summary
Transsphenoidal endoscopic surgery is the cornerstone of treatment for the majority of patients with pituitary tumors. A possible complication of surgery is the onset of new pituitary insufficiencies. This may eventually recover in Several tests are available for the assessment of adrenal function, of which the insulin tolerance test (ITT) is considered as the gold standard. The ITT, is not suitable for the immediate postoperative period, as it is burdensome, and has contraindications. The ACTH test may not detect cases of new-onset secondary adrenal insufficiency (AI). Alternatives are the CRH-stimulation test, the metyrapone test, and measurements of nonstimulated basal cortisol, or random serum cortisol
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.